Published in Pigment Cell Res on February 01, 2006
Oncogenic activities of metabotropic glutamate receptor 1 (Grm1) in melanocyte transformation. Pigment Cell Melanoma Res (2008) 1.37
Molecular pathways: dysregulated glutamatergic signaling pathways in cancer. Clin Cancer Res (2012) 1.10
Pharmacodynamics of memantine: an update. Curr Neuropharmacol (2008) 1.03
Metabotropic glutamate receptors (mGlus) and cellular transformation. Neuropharmacology (2008) 1.02
Metabotropic glutamate receptor 1 (Grm1) is an oncogene in epithelial cells. Oncogene (2012) 1.01
The role of the hippo pathway in melanocytes and melanoma. Front Oncol (2013) 0.90
Signaling Pathways in Melanogenesis. Int J Mol Sci (2016) 0.87
Metabotropic glutamate receptor 6 signaling enhances TRPM1 calcium channel function and increases melanin content in human melanocytes. Pigment Cell Melanoma Res (2013) 0.82
Anti-NMDAR encephalitis after resection of melanocytic nevi: report of two cases. BMC Neurol (2015) 0.80
Modulation of suicidal erythrocyte cation channels by an AMPA antagonist. J Cell Mol Med (2009) 0.78
Yokukansan, a traditional Japanese medicine, adjusts glutamate signaling in cultured keratinocytes. Biomed Res Int (2014) 0.76
Role of the G Protein-Coupled Receptor, mGlu1, in Melanoma Development. Pharmaceuticals (Basel) (2010) 0.76
Evidence That GRIN2A Mutations in Melanoma Correlate with Decreased Survival. Front Oncol (2014) 0.76
Autoimmune Encephalitis: An Expanding Frontier of Neuroimmunology. Chin Med J (Engl) (2016) 0.75
Integration of Next Generation Sequencing and EPR Analysis to Uncover Molecular Mechanism Underlying Shell Color Variation in Scallops. PLoS One (2016) 0.75
Improved detection of gene-microbe interactions in the mouse skin microbiota using high-resolution QTL mapping of 16S rRNA transcripts. Microbiome (2017) 0.75
Glutamate signalling in non-neuronal tissues. Trends Pharmacol Sci (2001) 1.91
A multicenter study on the use of pulsed low-intensity direct current for healing chronic stage II and stage III decubitus ulcers. Arch Dermatol (1993) 1.68
What are melanocytes really doing all day long...? Exp Dermatol (2009) 1.65
From the bench to the bedside: proton pump inhibitors can worsen vitiligo. Br J Dermatol (2007) 1.63
Vitiligo pathogenesis: autoimmune disease, genetic defect, excessive reactive oxygen species, calcium imbalance, or what else? Exp Dermatol (2008) 1.39
Senile hair graying: H2O2-mediated oxidative stress affects human hair color by blunting methionine sulfoxide repair. FASEB J (2009) 1.25
Effects of endothelial cells on human mesenchymal stem cell activity in a three-dimensional in vitro model. Eur Cell Mater (2011) 1.24
Expression and function of the apoptosis effector Apaf-1 in melanoma. Cell Death Differ (2005) 1.16
Melanocytes are not absent in lesional skin of long duration vitiligo. J Pathol (2000) 1.15
The role of thioredoxin reductase in the reduction of free radicals at the surface of the epidermis. Biochem Biophys Res Commun (1986) 1.14
Serum selenium levels and blood glutathione peroxidase activities in vitiligo. Br J Dermatol (1999) 1.11
Expression of an N-methyl-D-aspartate-type receptor by human and rat osteoblasts and osteoclasts suggests a novel glutamate signaling pathway in bone. Bone (1998) 1.08
Free radical reduction by thioredoxin reductase at the surface of normal and vitiliginous human keratinocytes. J Invest Dermatol (1986) 1.06
Mechanically regulated expression of a neural glutamate transporter in bone: a role for excitatory amino acids as osteotropic agents? Bone (1997) 1.04
Investigation of the personality structure in patients with vitiligo and a possible association with impaired catecholamine metabolism. Dermatology (1995) 1.04
Best5: a novel interferon-inducible gene expressed during bone formation. FASEB J (2000) 1.03
Evidence for targeted vesicular glutamate exocytosis in osteoblasts. Bone (2001) 0.95
The NMDA type glutamate receptors expressed by primary rat osteoblasts have the same electrophysiological characteristics as neuronal receptors. Calcif Tissue Int (2002) 0.93
Localization of ADAM10 and Notch receptors in bone. Bone (1999) 0.93
Pro-opiomelanocortin-related peptides, prohormone convertases 1 and 2 and the regulatory peptide 7B2 are present in melanosomes of human melanocytes. J Invest Dermatol (2000) 0.89
Studies on the reactions between human tyrosinase, superoxide anion, hydrogen peroxide and thiols. Biochim Biophys Acta (1991) 0.87
Thioredoxin reductase. Role in free radical reduction in different hypopigmentation disorders. Arch Dermatol (1987) 0.85
Regulation of pigmentation in human epidermal melanocytes by functional high-affinity beta-melanocyte-stimulating hormone/melanocortin-4 receptor signaling. Endocrinology (2008) 0.85
Ligand-dependent activation of the melanocortin 5 receptor: cAMP production and ryanodine receptor-dependent elevations of [Ca(2+)](I). Biochem Biophys Res Commun (2002) 0.84
Are unconventional NMDA receptors involved in slowly adapting type I mechanoreceptor responses? Neuroscience (2005) 0.82
The Ca2+-binding capacity of epidermal furin is disrupted by H2O2-mediated oxidation in vitiligo. Endocrinology (2008) 0.82
The allergenicity of complex cations. Biochem Biophys Res Commun (1986) 0.82
The effect of RBC transfusions on cytokine gene expression after cardiac surgery in patients developing post-operative multiple organ failure. Transfus Med (2011) 0.81
Off-targets effects underlie the inhibitory effect of FAK inhibitors on platelet activation: studies using Fak-deficient mice. J Thromb Haemost (2013) 0.80
H(2)O(2) increases de novo synthesis of (6R)-L-erythro-5,6,7,8-tetrahydrobiopterin via GTP cyclohydrolase I and its feedback regulatory protein in vitiligo. J Inherit Metab Dis (2008) 0.80
The role of calcium in the regulation of free radical reduction by thioredoxin reductase at the surface of the skin. J Inorg Biochem (1987) 0.79
Beta-adrenergic blocking drugs may exacerbate vitiligo. Br J Dermatol (1995) 0.79
Evidence for specific complex formation between alpha-melanocyte stimulating hormone and 6(R)-L-erythro-5,6,7,8-tetrahydrobiopterin using near infrared Fourier transform Raman spectroscopy. Biochemistry (1999) 0.79
Induction of contact dermatitis in guinea pigs by quaternary ammonium compounds: the mechanism of antigen formation. Environ Health Perspect (1986) 0.79
Melanocortins in human melanocytes. Cell Mol Biol (Noisy-le-grand) (2006) 0.78
Regulatory mechanisms of calcineurin phosphatase activity. Curr Med Chem (2011) 0.78
Non-transferrin bound iron measurement is influenced by chelator concentration. Anal Biochem (2008) 0.77
PUVA for vitiligo and skin cancer. Clin Exp Dermatol (1997) 0.77
The effect of UV radiation and sun blockers on free radical defence in human and guinea pig epidermis. Arch Dermatol Res (1990) 0.77
Does melanin affect the low LET radiation response of Cloudman S91 mouse melanoma cell lines? Pigment Cell Res (1991) 0.76
Calcium homeostasis influences epidermal sweating in patients with vitiligo. Br J Dermatol (1997) 0.76
Ultraviolet-A (UVA-1) radiation suppresses immunoglobulin production of activated B lymphocytes in vitro. Clin Exp Immunol (2006) 0.76
Effectiveness of pseudocatalase formulations in vitiligo. Clin Exp Dermatol (2003) 0.75
GTP-cyclohydrolase and vitiligo. Lancet (1997) 0.75
Downregulation of tyrosinase activity in human melanocyte cell cultures by yohimbine. J Invest Dermatol (2000) 0.75
Human epidermal proopiomelanocortin (POMC) cDNA variant is identical to mouse POMC cDNA. J Invest Dermatol (1999) 0.75
GTP-cyclohydrolase I and vitiligo. Clin Exp Dermatol (2000) 0.75
A probable mechanism for hyperpigmentation by fotemustine. Dermatology (1992) 0.75
Nitroxide radical reduction in nude mouse skin. J Invest Dermatol (1990) 0.75
Integrin receptor involvement in actin cable formation in an in vitro model of events associated with wound contraction. Int J Biochem Cell Biol (1997) 0.75
An uncommon onset of myeloma. J Am Acad Dermatol (1985) 0.75
Tryptophan protects human melanoma cells against gamma-interferon and tumour necrosis factor-alpha: a unifying mechanism of action. Melanoma Res (1992) 0.75
[Risk factors for skin melanoma: genetic factors probably more important than exposure to sunlight]. Ned Tijdschr Geneeskd (2004) 0.75
Pseudocatalase treatment in xeroderma pigmentosum: a case report. Br J Dermatol (1999) 0.75
[Eosinophilia-myalgia syndrome. Clinical aspects and follow-up of 10 patients]. Hautarzt (1992) 0.75
In vivo and in vitro evidence for autocrine DCoH/HNF-1alpha transcription of albumin in the human epidermis. Exp Dermatol (2005) 0.75
m2 muscarinic acetylcholine receptor (mAchR) subtype is present in human epidermal keratinocytes in situ and in vivo. J Invest Dermatol (2004) 0.75
A comparative study of the allergenicity of quaternary ammonium compounds in guinea-pigs. Clin Exp Dermatol (1986) 0.75
[Vitiligo]. Hautarzt (1997) 0.75
Total serum immunoglobulins and atopic symptoms in patients with vitiligo. Dermatology (1994) 0.75
Clinical evaluation of a dioic acid-based formulation on facial skin in an Indian population. Int J Cosmet Sci (2012) 0.75
[Ulcerative angiosarcoma of the cranial vault masquerading as a pyoderma]. Rontgenblatter (1989) 0.75
In vivo delayed-type hypersensitivity in 109 patients with vitiligo. Int J Dermatol (2000) 0.75